Table 6 Ongoing clinical trials phase 3 studies
From: COVID-19 pandemic crisis—a complete outline of SARS-CoV-2
Study title | Conditions | Interventions | Locations |
|---|---|---|---|
Randomized evaluation of COVID-19 therapy | Severe acute respiratory syndrome | Drugs: hydroxychloroquine, lopinavir/ritonavir, corticosteroid, azithromycin, tocilizumab | Nuffield Department of Population Health, University of Oxford, Oxford, UK |
Hydroxychloroquine and zinc with either azithromycin or doxycycline for treatment of COVID-19 in outpatient setting N | COVID-19 | Drugs: hydroxychloroquine, azithromycin, zinc sulfate, doxycycline | St. Francis Hospital, Roslyn, NY, USA |
Favipiravir in hospitalized COVID-19 patients | COVID-19 | Drugs: favipiravir, hydroxychloroquine | Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran |
Baricitinib therapy in COVID-19 | COVID-19 pneumonia | Drug: baricitinib 4 mg oral tablet | Fabrizio Cantini, Prato, Tuscany, Italy |
Treatment for COVID-19 in high-risk adult outpatients | COVID-19 SARS-CoV-2 | Drugs: ascorbic acid, hydroxychloroquine sulfate, azithromycin, folic acid | • Boston University, Boston, MA, USA • University of Washington Coordinating Center, Seattle, Washington, USA • UW Virology Research Clinic, Seattle, WA, USA and 4 more |
Convalescent plasma for hospitalized adults with COVID-19 respiratory illness (CONCOR-1) | COVID-19 | Other: convalescent plasma | • Vancouver General Hospital, Vancouver, British Columbia, Canada • Victoria General Hospital, Victoria, British Columbia, Canada • London Health Sciences Centre—University Hospital, London, Ontario, Canada and 25 more |
BCG vaccine for health care workers as defense against COVID-19 | Coronavirus infection, Coronavirus as the cause of diseases classified elsewhere | Biologicals: BCG vaccine, placebo vaccine | • Harvard T.H. Chan School of Public Health, Boston, MA, USA • Baylor College of Medicine, Houston, TX, USA • MD Anderson Cancer Center, Houston, TX, USA and 4 more |
Outcomes related to COVID-19 treated with hydroxychloroquine among in-patients with symptomatic disease | Coronavirus acute respiratory infection -SARS-CoV infection | • Drugs: hydroxychloroquine, placebo | • Stanford University, Stanford, CA, USA • University of Colorado Hospital, Aurora, CO, USA • Denver Health Medical Center, Denver, CO, USA and 40 more |
Treatment of COVID-19 patients with anti-interleukin drugs | COVID-19 | • Other: usual care • Drugs: anakinra, siltuximab, tocilizumab | • University Hospital Saint-Pierre, Brussels, Belgium • University Hospital Antwerp, Edegem, Belgium • University Hospital Brussels, Jette, Belgium 13 more |
Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with severe coronavirus disease (COVID-19) | COVID-19 | Drug: remdesivir | • Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, CA, USA • Alta Bates Summit Medical Center, Berkeley, CA, USA • Mills-Peninsula Medical Center, Burlingame, CA, USA and180 more |